endTB Study Group Members

December 8, 2019

The endTB Study Group is the group that is responsible for the endTB Observational Study (NCT02754765), which includes more than 2700 patients started on bedaquiline and delamanid containing regimens in 17 countries. Organized by country, this is a list of doctors, nurses, data managers, pharmacists, social workers, administrators and others who have spent many hours collecting and cleaning data, working closely with patients, and ensuring that the endTB Observational Study works smoothly in every aspect of its complex existence.

DR-TB Drugs Under the Microscope: 6th edition

November 7, 2019

This MSF Access Campaign report – now in its sixth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs in the framework of the new 2019 WHO DR-TB guidelines.

We provide detailed pricing profiles of key DR-TB drugs available on the Global TB Drug Facility website and estimated prices of DR-TB regimens recommended by WHO in programmatic or operational research frameworks.

This report was produced using among others endTB observational cohort data.

Technical Basis of the endTB Observational Study (EN/RU/ES/FR)

January 20, 2019

This Technical Basis document provides the rationale for clinical decision-making, screening tools, and data definitions that are used at the endTB Observational Study sites. This is a living document. If you would like to suggest an additional topic, please email us at endTB1@pih.org.

The Technical Basis document is available in English, Russian, Spanish and French.

DR-TB Drugs Under the Microscope: 5th edition

November 26, 2018

This MSF Access Campaign report – now in its fifth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs.

We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to standardised questionnaires and the Global TB Drug Facility website.

This report was produced with endTB's support.

endTB Interim Analysis Report (EN / ES / RUS)

July 13, 2018
Bedaquiline- and delamanid- containing regimens achieve excellent interim treatment response without safety concerns: This report presents the results of three different analyses (a safety analysis, a delamanid analysis, and an injectables analysis) to improve the evidence base for using bedaquiline and delamanid in drug-resistant TB regimens. Available in English, Spanish, and Russian.

endTB Clinical Guide v4.0 (EN / RU / ES / FR)

February 9, 2018

This guide is designed to give guidance to the endTB Project site on the use of new TB drugs bedaquiline and delamanid.

It is intended to be a resource for physicians and other health care professionals involved in the endTB project.

The clinical guide is available in English, Russian, Spanish and French.

eLearning modules

February 8, 2018
​​​​​​The following eLearning units have been developed to provide guidance to physicians caring for MDR-TB patients enrolled in the endTB project.

Patent Opposition Database

January 10, 2018

The Patent Opposition Database is a site that allows civil society to share resources and learn about the tools needed to oppose the application or granting of unwarranted patents on medicines. The site contains a wealth of information on existing patent oppositions, patent applications, patent office decisions, court cases and other vital documents that will inform users own preparation for filing an opposition by sharing these resources and the experience of others.


Out of Step: TB policies in 29 countries, 3rd Ed. (2017)

September 19, 2017

Although it can be prevented and successfully treated, tuberculosis (TB) is the world’s deadliest infectious disease: in 2015, 1.8 million people died from it. While there have been substantial and important innovations in the fight against TB, including faster, more accurate diagnostic tests and the first new medicines in nearly 50 years, deadly gaps remain in implementing and providing access to these advances.